Ibrutinib for patients with rituximab-refractory Waldenström’s macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.

The Lancet Oncology

December 9, 2016 

Dimopoulos, Meletios A et al.